Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models
Journal
Vaccine
Journal Volume
25
Journal Issue
16 SPEC. ISS.
Pages
3038-3040
Date Issued
2007
Author(s)
Okada M.
Okuno Y.
Hashimoto S.
Kita Y.
Kanamaru N.
Nishida Y.
Tsunai Y.
Inoue R.
Nakatani H.
Fukamizu R.
Namie Y.
Yamada J.
Takao K.
Asai R.
Asaki R.
Kase T.
Takemoto Y.
Yoshida S.
Peiris J.S.M.
Yamamoto N.
Nomura T.
Ishida I.
Morikawa S.
Tashiro M.
Sakatani M.
Abstract
We have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupted SCID mice, and SCID-PBL/hu mice were constructed. These mice can be used to analyze the human immune response in vivo. SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed. These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines. © 2007 Elsevier Ltd. All rights reserved.
SDGs
Publisher
Elsevier BV
Type
journal article